Nanalysis Scientific Valuation
Is NSCI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NSCI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NSCI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NSCI's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NSCI?
Key metric: As NSCI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is NSCI's PS Ratio? | |
|---|---|
| PS Ratio | 1.1x |
| Sales | CA$39.47m |
| Market Cap | CA$42.98m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | -6.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NSCI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 31x | ||
PINK Perimeter Medical Imaging AI | 55.8x | 63.4% | CA$56.0m |
ASG Aurora Spine | 1.4x | n/a | CA$33.3m |
NGMD NuGen Medical Devices | 56.5x | n/a | CA$19.6m |
CNVI Conavi Medical | 10.4x | n/a | CA$38.1m |
NSCI Nanalysis Scientific | 1.1x | n/a | CA$43.0m |
Price-To-Sales vs Peers: NSCI is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (31x).
Price to Sales Ratio vs Industry
How does NSCI's PS Ratio compare vs other companies in the CA Medical Equipment Industry?
| 8 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 3.2x | 8.2% | |
NSCI Nanalysis Scientific | 1.1x | n/a | US$30.78m |
HTL Hamilton Thorne | 3.3x | 9.1% | US$247.98m |
ASG Aurora Spine | 1.4x | n/a | US$23.84m |
| 8 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 3.2x | 17.1% | |
NSCI Nanalysis Scientific | 1.1x | n/a | US$30.78m |
Price-To-Sales vs Industry: NSCI is good value based on its Price-To-Sales Ratio (1.1x) compared to the North American Medical Equipment industry average (3.2x).
Price to Sales Ratio vs Fair Ratio
What is NSCI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NSCI's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
NeuPath Health
CA$9.3m
Provides chronic pain management services in Canada.
NPTH
CA$0.16
7D
-3.0%
1Y
3.2%
Hamilton Thorne
CA$346.3m
Develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets.
HTL
CA$2.25
7D
0.9%
1Y
77.2%
Medical Facilities
CA$374.5m
Through its subsidiaries, owns and operates specialty hospitals and ambulatory surgery center in the United States.
DR
CA$15.73
7D
4.9%
1Y
82.5%